Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $25.0M | $0 | $451.0K | $6.0K | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $25.0M | $0 | $451.0K | $6.0K | $0 | $0 | $0 |
| Gross margin | — | 100.0% | — | 100.0% | 100.0% | — | — | — |
| R&D | $36.3M | $41.8M | $4.4M | $24.3M | $39.2M | $41.1M | $60.9M | $75.0M |
| Operating income | −$51.1M | −$32.6M | −$71.0M | −$33.7M | −$60.7M | −$59.1M | −$82.6M | −$103.3M |
| EBITDA | −$50.2M | −$31.5M | −$21.4M | −$31.9M | −$60.7M | −$53.4M | $3.2M | $3.1M |
| Net income | −$50.2M | −$31.6M | −$69.4M | −$33.3M | −$60.7M | −$57.6M | −$75.1M | −$90.4M |
| Net margin | — | -126.3% | — | -7378.5% | -1011533.3% | — | — | — |
| EPS (diluted) | -10.70 | -1.34 | -12.85 | -3.20 | -5.50 | -5.07 | -3.96 | 0.00 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds NLTX.
No tracked institution reports a position in NLTX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-12-19 | 1-for-4reverse |
| 2013-11-21 | 1-for-50reverse |
No one on the platform has traded NLTX yet.
| $9M |
| — |
| DMKPQDMK Pharmaceuticals Corporation | $0.00 | +0.00% | $1010 | — |
| LCILannett Company, Inc. | $0.69 | +0.00% | $7M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$NGNE $NLTX Just got 7.2 cents per NLTX CVR. It’s basically exactly one year since last distribution.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.